



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2024-25/BSE/302

Dated:13.02.2025

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 13th February 2025 with Scrip Code 524703.

Ref: Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

A Meeting of the Board of Directors of the Company duly convened on Thursday, 13th February 2025 at 02:00 p.m. and Concluded at 5:15 p.m. discussed the following business:-

1. The Unaudited Standalone Financial Results of the Company for the quarter ended 31st December, 2024 and the Limited Review Report issued by M/s. Dileep & Prithvi, Chartered Accountants, Mumbai, [Firm Registration. No. 122290W], Statutory Auditors of the Company pursuant to Regulation 33 of Chapter IV of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and placed before the Board of Directors of the Company in their meeting held today. The same is approved and taken on record by the Board.

The Unaudited Standalone Financial Results for the quarter ended 31st December 2024 and the Limited Review Report will also be made available at the website of the company at www.sandu.in and are enclosed herewith for your kind perusal.

Further, We would like to inform you that pursuant to sale of investment of its entire stake by Sandu Pharmaceuticals Limited in Sandu Phytoceuticals Private Limited-Wholly owned Non Material Subsidiary ,Company is not required to do consolidation of Financials for the Q ended 31st December 2024 and onwards.

2. On Recommendation of Audit Committee ,Board of Director has Considered and Appointed M/S Akhil Pai & Co, as the internal Auditor of Goa Plant Operations And M/S Uday & Uday Associates Chartered Accountant as The Internal Auditor for Mumbai For The Financial Year 2025-26. The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I.
3. Resignation of Smt. Shubhada Sandu as Non Executive Non Independent Director(DIN:07148834) of the Company .

The Board took note of the resignation tendered by Smt. Shubhada Sandu (DIN: 07148834) Director who will step down from the position of the Non Executive, Non Independent Director of the Company with effect from the close of business hours on 13th February 2025.

Smt. Shubhada Sandu has confirmed that there is no other material reasons for her resignation as Non Executive Non Independent Director other then stated in the resignation letter and also has informed that she doesn't hold any directorship or membership in any of the Board Committees of the any Listed Companies.

Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, with regard Smt. Shubhada Sandu is given herein under: - Annexure II



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

FOR SANDU PHARMACEUTICALS LIMITED.

Pratika Mhambray
Company Secretary
ACS :36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



Annexure-I

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr No	Details of events that need to be provided	Information of such event(s)	
		1. M/S Akhil Pai & Co	2. M/S Uday & Uday Associates
<u>1</u>	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Considering the term of expiry of internal auditor for Goa Plant operations, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2025-26 .	Considering the term of expiry of internal auditor for Mumbai, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2025-26
<u>2</u>	Date of appointment/ Cessation and terms of appointment;	01.04.2025	01.04.2025
<u>3</u>	Brief Profile (in case of appointment);	He is Practising Chartered Account . he has conducted Tax Audits of Proprietorship Concerns, Firms and Companies, and also look into other Companies law matters, Income Tax related & GST matters.	Practicing chartered Accountant firm specialized in Companies Audit ,Cooperative Sector Audit ,Nationalized Bank Audit etc.
<u>4</u>	Disclosure of relationships between directors. (in case of Appointment)	Akhil Pai & Co is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company.	Uday & Uday Associates is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company.

Annexure-II

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr No	Details of events that need to be provided	Smt Shubhada Sandu (DIN: 07148834)
1	Reason for change viz. appointment, resignation, removal, death or otherwise Completion of their terms	Resignation of Smt Shubhada Sandu as Non Executive Non Independent Director (DIN: 07148834)
2	Date of appointment/ Cessation and terms of appointment;	From the Closure of business hours on 13 th February 2025
3	Brief Profile (in case of appointment);	Not Applicable
4	Disclosure of relationships between directors. (in case of Appointment)	Not applicable
5	Letter of Resignation along with detailed reasons for resignation	Smt Shubhada Sandu (DIN: 07148834) has tendered resignation due to her advanced age, she has not been keeping good health and therefore, she has submitted her resignation as Non-Executive Non independent Director of the Company
6	Names of the listed entities in which the resigning Director holds directorship and membership of Board committees, if any.	Smt Shubhada Sandu (DIN: 07148834) has informed that she does not hold any directorship and membership of Board committees in any listed entity
7.	The confirmation that there are no other material reasons other than those provided	Smt Shubhada Sandu (DIN: 07148834) has confirmed that there are no other material reasons for her resignation other than those mentioned in his resignation letter dated February 13, 2025.

FOR SANDU PHARMACEUTICALS LIMITED.

Pratika Mhambray
Company Secretary
ACS :36512



Standalone Statement of Profit and loss account for the period ended December - 2024

(Rs. in Lakhs)

Particulars	QUARTER ENDED			NINE MONTHS ENDED		PREVIOUS YEAR
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	Previous Year Ended 31-03-2024
	Unaudited Amount (₹)	Unaudited Amount (₹)	Unaudited Amount (₹)	Unaudited Amount (₹)	Unaudited Amount (₹)	Audited Amount (₹)
INCOME						
Revenue From Operations	1837.29	1770.49	1742.87	5,312.32	5168.30	6728.07
Other Income	2.45	2.87	2.67	9.81	11.47	42.13
Total Income	1839.74	1773.36	1745.54	5,322.13	5179.77	6770.20
EXPENSES						
Cost of materials consumed	239.21	243.86	241.70	710.48	701.06	985.26
Purchases of Stock-in-Trade	654.78	540.64	641.40	1,589.52	1548.79	2108.28
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(7.74)	31.58	(20.44)	332.33	387.19	163.48
Employee benefits expense	315.71	260.76	253.38	809.29	760.33	1007.32
Finance costs	2.74	2.83	1.76	7.70	5.58	6.31
Depreciation and amortization expense	18.96	17.41	14.17	52.24	39.68	58.33
Other expenses	536.23	601.90	575.74	1,639.24	1601.62	2234.00
Total expenses	1759.89	1698.97	1707.70	5,140.80	5044.26	6562.97
Profit/(loss) before exceptional items and tax	79.85	74.39	37.84	181.33	135.50	207.24
Exceptional Items / Prior Period Adjustment						
PROFIT/(LOSS) BEFORE TAX	79.85	74.39	37.84	181.33	135.50	207.24
Tax expense:						
Current tax	(22.92)	(20.97)	(10.72)	(51.45)	(37.66)	(58.71)
Deferred tax	(1.38)	(3.40)	(6.42)	(7.65)	(11.03)	(2.46)
Short / (Excess) Tax Provision						
PROFIT (LOSS) FOR THE PERIOD	55.55	50.02	20.70	122.25	86.81	146.07
OTHER COMPREHENSIVE INCOME						
Items that will not be reclassified to profit or loss in Subsequent Periods:						
Remeasurement gains/(losses) on post employment defined benefit plans						(11.96)
Fair value changes of investments	20.54	19.94	17.75	61.60	55.68	78.90
Income tax relating to items that will not be reclassified to profit or loss	(2.29)	(2.22)	(3.99)	(6.86)	(6.20)	(5.45)
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	18.25	17.72	13.76	54.74	49.48	61.49
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	73.80	67.74	34.45	176.99	136.29	207.56
Paid up Equity Capital (Face Value of Rs. 10/- per share)	966.10	966.10	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE						
Basic	0.57	0.52	0.21	1.27	0.90	1.51
Diluted	0.57	0.52	0.21	1.27	0.90	1.51



For Sandu Pharmaceuticals Ltd.



Umesh B. Sandu
(Managing Director)
DIN:01132141


Mumbai
Dt: 13.02.2025

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 13th February 2025.
4. The Figures for the quarter ended 31 st March, 2024 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. We would like to inform you that pursuant to sale of investment of its entire stake by Sandu Pharmaceuticals Limited in Sandu Phytoceuticals Private Limited-Wholly owned Non Material Subsidiary and therefore the company is not required to do consolidation of Financials for the Q ended 31st December 2024 and onwards.

Date: - 13/02/2025

For Sandu Pharmaceuticals Ltd




Umesh Sandu
Managing Director
DIN no: - 01132141


**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE
FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER,
2024**

To,
The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and nine months ended on 31st December, 2024, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W



Himmat Mali
(Partner)
Membership Number: 183378
UDIN- 25183378BMNAPV3531



Place: Mumbai
Date: 13th February, 2025

DR MRS SHUBHADA SANDU
3, KRISHNA BHAVAN, 7TH CROSS ROAD
NEAR DIAMOND GARDEN, CHEMBUR-400071

February 13, 2025

To,
The Board of Directors
Sandu Pharmaceuticals Limited
Plot No 25, 26, 29 & 30
Pilerne Industrial Estate, Marra
Saligao Bardez Goa 403511

Sub: Resignation from the post of Non Executive Non Independent Director of Sandu Pharmaceuticals Limited.

Dear Sir/Madam,

I, Shubhada Sandu, appointed as Non Executive Non Independent Director (holding DIN No: 07148834) of your Company hereby resign from the position with immediate effect after closure of business hours dated 13th February 2025.

This decision was not easy, but I believe it is time for me to looking after my declining /deteriorating age. I am grateful for the support and collaboration I have experienced during my tenure and for the valuable relationships I have built with each of you.

I would like to confirm that

- 1) there is no other material reasons for my resignation other than those stated above.
- 2) i don't hold any directorship or membership in any of the Board Committees of the any Listed Companies.

I am committed to ensuring a smooth transition and will do everything I can to facilitate this process despite my immediate resignation.

It has been a privilege to work alongside such a dedicated and talented team. I am grateful for the opportunities I've had to contribute to our goals and witness our collective achievements.

Thank you for your understanding and support. I wish the team continued success in the future.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies and Stock Exchange(s) to that effect.

Thanking You,
Yours Sincerely,

Shubhada

DR MRS SHUBHADA SANDU
3, KRISHNA BHAVAN, 7TH CROSS ROAD
NEAR DIAMOND GARDEN, CHEMBUR-400071
DIN: 07148834

Name - Umesh Sandu,

Designation : Managing Director
DIN : 01132141



*can be accepted
13/02/25.*